Version June 2024
| Clinical behavior | Treatment and treatment goal | Monitoring strategy |
| Potentially reversible with risk of irreversible disease (eg, cases of drug-related lung disease in RA) | Remove cause, treat to obtain a response to reverse changes | Short-term (three to six months) observation to confirm disease regression, or occasionally need for palliation |
| Reversible disease with risk of progression (eg, RA-cellular NSIP and some RA-fibrotic NSIP, RA-OP) | Treat to initially achieve response and then rationalize longer term therapy | Short-term observation to confirm treatment response. Long-term observation to ensure that gains are preserved |
| Stable with residual disease (eg, some RA-fibrotic NSIP, some RA-UIP) | No treatment if stable, aiming to maintain status | Long-term observation to assess disease course |
| Progressive, irreversible disease with potential for stabilization (eg, some RA-fibrotic NSIP, some RA-UIP) | Consider treatment trial to stabilize | Long-term observation to assess disease course |
| Progressive, irreversible disease despite therapy (eg, RA-DAD, most RA-UIP, some RA-fibrotic NSIP) | In absence of contraindications, consider treatment trial in selected patients to slow progression | Short (DAD) or long-term observation to assess disease course, and need for transplant or effective palliation |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
